Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab

Annals of Hematology

Volumn 90, Issue 10, 2011, Pages 1131-1136

  Gruber, Michaela ^a   Fleiss, Karin ^a   Porpaczy, Edit ^a   Skrabs, Cathrin ^a   Hauswirth, Alexander W ^a   Gaiger, Alexander ^a   Vanura, Katrina ^a   Heintel, Daniel ^a   Shehata, Medhat ^a   Einberger, Christine ^a   Thalhammer, Renate ^a   Fonatsch, Christa ^a   Jäger, Ulrich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CLL; Dose intensity; Fludarabine cyclophosphamide rituximab; G CSF; Progression free survival

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; HEMATOLOGIC AGENT; MONOCLONAL ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VIDARABINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; BLOOD; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; DRUG MONITORING; MIDDLE AGED; PATHOPHYSIOLOGY; PILOT STUDY; RETROSPECTIVE STUDY; SURVIVAL;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG MONITORING; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOLOGIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEUTROPENIA; PILOT PROJECTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VIDARABINE;

EID: 80055099342     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1260-x     Document Type: Article

References (24)

1. Keating MJ, O'Brien S, Albitar M et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088 (Pubitemid 46211313)
2. Wierda W, O'Brian S, Wen S et al (2005) Chemotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078 (Pubitemid 46211312)
3. Gribben JG (2010) How I treat CLL upfront. Blood 115:187-197
4. Hallek M, Fingerle-Rowson G, Fink AM et al (2010) The addition of rituximab to fludarabine and cyclophosphamide improves the overall survival of patients with chronic lymphocytic leukemia. Lancet 376:1164-1174
5. Robak T, Dmoszynska A, Solal-Céligny P et al (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756-1765
6. Tam CS, O'Brien S, Wierda W et al (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975-980
7. Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the InternationalWorkshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 111:5446-5456
8. Cheson BD, Bennett JM, Grever M et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990-4997 (Pubitemid 26189840)
9. American Society of Clinical Oncology (1994) American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508
10. Falandry C, Campone M, Cartron G, Guerin D, Freyer G (2010) Guidelines EORTC/Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer 46:2389-2398
11. Pfreundschuh M, Trümper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641 (Pubitemid 38970554)
12. Pettengell R, Schwenkglenks M, Bosly A (2008) Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 87:429-430
13. Pettengell R, Gurney H, Radford JA et al (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 80:1430-1436
14. Foon KA, Boyiadzis M, Land SR et al (2009) Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:498-503
15. Ahmadi T, Schuster SJ (2009) Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned? J Clin Oncol 27:479-480
16. Wierda WG, O'Brien S, Wang X et al (2009) Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 27:1637-1643
17. Selenko N, Majdic O, Jäger U, Sillaber C, Stöckl J, Knapp W (2002) Cross-priming of cytotoxic T cells promoted by apoptosisinducing tumor cell reactive antibodies? J Clin Immunol 22:124-130 (Pubitemid 34596935)
18. Stockmeyer B, Schiller M, Repp R et al (2002) Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factorprimed effector cells and Hu1D10-a humanized human leucocyte antigen DR antibody. Br J Haematol 118:959-967 (Pubitemid 35025957)
19. Ferrajoli A (2009) Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 50:514-516
20. Crawford J, Ozer H, Stoller R et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 325:164-170
21. Trillet-Lenoir V, Green J, Manegold C et al (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29:319-324 (Pubitemid 23025731)
22. Mayordomo JI, Rivera F, Diaz Puente MT et al (1995) Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 87:803-808
23. Timmer-Bonte J, Adang EM, Smit JH et al (2006) Costeffectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol 24(19):2991-2997 (Pubitemid 46638931)
24. Elting LS, Lu C, Escalante CP et al (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606-611 (Pubitemid 351264355)